Last reviewed by Daniel Gana, MSc, Dr. Abraham Benavides, MD, and Brent Ristow PhD, JD, 12-18-2024.

When people think about antiviral agents, they often imagine pharmaceutical drugs like acyclovir or valacyclovir, which have long been the go-to treatments for viral infections such as herpes. However, these conventional antiviral medications are less effective especially for immunocompromised individuals, as viruses like the herpes simplex virus (HSV) demonstrate resistance. 

Herpes is caused by the herpes simplex virus (HSV). It is a widespread viral infection affecting over 3.8 billion people worldwide. It exists in two primary forms, namely: 

1. HSV-1 (Oral herpes): HSV-1 is frequently asymptomatic but primarily responsible for oral herpes, often causing painful sores or blisters around the mouth. It is highly contagious and can be spread through direct contact with an infected person’s saliva. While it is most commonly associated with oral outbreaks, HSV-1 can also lead to genital herpes among various other presentations in some cases through oral-genital contact. Once infected, the virus remains dormant in nerve cells (latent) and can reactivate later, leading to recurrent outbreaks, often triggered by factors like stress or a weakened immune system.
   
2. HSV-2 (Genital herpes): HSV-2 is the main cause of genital herpes, leading to painful sores in the genital and anal areas. It is primarily spread through sexual contact or infected body fluids. Like HSV-1, HSV-2 can cause an initial outbreak, and remain dormant in the body’s nerve cells and reactivate periodically, causing outbreaks. Although HSV-2 infections are lifelong, antiviral treatments can help manage symptoms and reduce the frequency of outbreaks. 

While current treatments of herpes focus on managing outbreaks and reducing the risk of transmission, they don’t eliminate the virus. The ability of HSV to develop resistance to available medications, evade the immune system, and establish latency poses significant challenges in treatment, driving the search for more effective solutions like plant-based medicines.

Cannabis As An Antiviral Agent

The antiviral potential of cannabis-based compounds like cannabinoids, flavonoids, and terpenes are widely studied, highlighting their ability to modulate immune responses and inhibit viral replication. 

These natural compounds interact with the endocannabinoid system and dozens of other receptors and molecular targets, offering therapeutic possibilities for various viral infections. 

Research suggests cannabinoids may offer antiviral activity against herpes simplex virus (HSV), hepatitis C virus (HCV), HIV, influenza virus, SARS-CoV-2 (COVID-19), Epstein-Barr virus (EBV), Kaposi’s sarcoma-associated herpesvirus (HSHV/HHV-8), and Zika virus. Their anti-inflammatory and immune-regulating properties may help manage symptoms and improve overall health. 

These compounds offer a broad-spectrum antiviral effect, meaning they have the potential to target and inhibit a wide range of viruses. Their antiviral effects are believed to stem from the following activities:

1. Inhibiting viral entry into host cells
2. Limiting viral replication 
3. Stimulating cellular innate immune response 
4. Regulating immune cell activity 
5. Reducing inflammation

How Cannabis Disarms Herpes Simplex Virus

A successful viral infection depends on certain factors including cellular entry, immune evasion, and invasion, replication, and mutation. While these are complex processes, research into the roles of cannabis as an antiviral has shown promise in disarming these weapons in the following ways: 

• Disrupting Cellular Entry Of Viruses 

Enveloped viruses, like HSV and SARS-COV-19, rely on spike proteins to initiate infection by binding to specific receptors on host cells. They work like “keys,” helping the virus attach to specific “locks” on human cells, such as nectin-1 or ACE2 receptors. Once the virus attaches, the spike proteins facilitate the virus’ entry into the cell, enabling it to hijack the host’s cellular processes for replication and spread.

Research suggests that cannabinoids, particularly CBD, CBGA, and CBDA, may interfere with this binding process by altering the conformation of spike proteins making them unable to bind to receptors on host cells. This ultimately reduces the virus’ chance of entering the cells to initiate an infection.  

Myrcene and pinene, for instance, are shown to have a calming effect on cellular processes, which may reduce the ability of viruses to attach to their target cells. Additionally, some terpenes may modify cell membranes, making it harder for spike proteins to bind and penetrate the host cell.

Flavonoids in cannabis such as vitexin and apigenin have strong antioxidant and antiviral properties. They may interfere with the spike proteins by disrupting the protein-protein interactions required for the virus to bind to host cells. 

• Promoting Immune Responses 

After a successful cellular entry, viruses survive by hiding within cells or manipulating immune responses, thereby making it harder for the body to recognize and eliminate them. 

Cannabinoids such as CBD, CBDA, THC, CBG, CBC, and more modulate several immune functions, supporting a balanced response. CBD and CBDA enhance anti-inflammatory effects, while also boosting innate immune cell activity, making them more effective at targeting infected cells. 

Terpenes like limonene, pinene, myrcene, linalool, and caryophyllene also play key roles in preventing immune invasion. Limonene and pinene are found to reduce viral infectivity of HSV-1 by 100%. Caryophyllene directly activates immune receptors, enhancing the body’s defense system.

Flavonoids, including cannflavins, quercetin, vitexin, rutin, apigenin, naringenin, kaempferol, and more, have antiviral and anti-inflammatory effects that reduce oxidative stress, block viral replication, and improve immune responses. Cannflavins specifically help reduce cytokine-induced damage, promoting better viral control.

• Preventing Viral Replication and Mutation

Once inside the host cell, viruses replicate rapidly and mutate, allowing them to spread quickly and potentially develop resistance to treatments.

Cannabis helps prevent viral replication and mutation through its cannabinoids, terpenes, and flavonoids, which interact with viral mechanisms. Cannabinoids like CBD, CBDA, and THC can disrupt viral replication by inhibiting the enzymes and proteins viruses need to replicate. For example, CBD is shown to interfere with the replication cycle of many viruses by inhibiting their ability to replicate within host cells.

Terpenes, such as caryophyllene, limonene, and pinene, have antiviral effects that can synergize with other whole-plant components to reduce viral load by interfering with the virus’s ability to replicate. Limonene, in particular, is shown to possess antiviral properties that target and block viruses like HSV-1 and SARS-CoV-2 from spreading within the body.

Flavonoids, such as cannflavins and quercetin, can reduce oxidative stress and inflammation caused by viral replication. This helps prevent cellular damage and limits the spread of the virus by supporting a stronger immune response and reducing the opportunities for the virus to replicate.

Bringing An End To The Debate: Isolate Vs. Full Spectrum Compounds As Antiviral Agents

While the antiviral activity of cannabinoids, terpenes, and flavonoids is widely reported by several researchers in preclinical research, their combined activity is found to produce better effects. For instance, a 2021 study published in Molecules highlighted how the bioactivity of industrial hemp is largely related to the presence of CBD, CBDA, flavonoids, polyphenols, and terpenes. These compounds work together synergistically, enhancing their overall antiviral and anti-inflammatory effects.

Another in vitro study published in the International Journal of Molecular Sciences revealed that a terpene-rich formulation of β-caryophyllene, eucalyptol, and citral showed increased antiviral potency when combined with CBD, suggesting that the combination amplifies their effects. This synergy is unique to full-spectrum formulations and absent in isolates, which contain a single  compound.

Full-spectrum products leverage the “entourage effect,” where multiple compounds interact to provide broader and more effective antiviral activity. In contrast, isolates, while precise, lack this interaction and may offer limited efficacy. 

However, not all full-spectrum extracts are made equal. The quality of your full-spectrum extract is imperative, as it determines the quantity of these therapeutic compounds and synergies you’ll get.

Full-spectrum cannabis extracts like our Active Spectrum Extracts TM comprise a more complete whole-plant profile than others due to the presence of flavonoids. Extracts like these may present a promising avenue for the potential management of HSV and other viral infections with a rich profile of cannabinoids, terpenes, and flavonoids. The combined effects of these extracts show a huge potential in reducing viral replication, alleviating symptoms, and enhancing immune response. 

References:

1. Centers for Disease Control and Prevention. Thousands of HSV DNA polymerase genes cloned. PubMed Central.pmc.ncbi.nlm.nih.gov/articles/PMC145299
2. World Health Organization. Herpes simplex virus. Retrieved fromwww.who.int/news-room/fact-sheets/detail/herpes-simplex-virus
3. Wallace, J. M., Tytell, A. A., & Sirois, R. A. (1991). Delta-9-Tetrahydrocannabinol (THC) effects on herpes simplex virus infectivity. PubMed, 1848937.pubmed.ncbi.nlm.nih.gov/1848937/
4. Ribeiro, A., Almeida, V. I., & Macedo, G. E. (2017). Screening of cannabidiol (CBD) as antiviral. PubMed Central.pmc.ncbi.nlm.nih.gov/articles/PMC5330095/
5. Molina, P. E., Amedee, A. M., & Winsauer, P. J. (2019). Cannabinoids inhibit productive HIV infection. PubMed Central, PMC6340429.pmc.ncbi.nlm.nih.gov/articles/PMC6340429/
6. Da Silva, J. F., Duarte, J. L., & Da Silva, T. C. (2024). Terpenes’ antiviral activity against HCoV-OC43 and influenza A virus. ScienceDirect.www.sciencedirect.com/science/article/pii/S2215017X2400002X
7. Janecki, M., Graczyk, M., Lewandowska, A. A., & Pawlak, Ł. (2022). Anti-inflammatory and antiviral effects of cannabinoids in inhibiting and preventing SARS-CoV-2 infection. International Journal of Molecular Sciences, 23(8), 4170.doi.org/10.3390/ijms23084170
8. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H., & Medveczky, P. G. (2004). Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Medicine, 2, 34.doi.org/10.1186/1741-7015-2-34
9. DerMardirossian, C. M., et al. (2006). THC inhibits KSHV and EBV reactivation. PubMed Central, PMC521080.pmc.ncbi.nlm.nih.gov/articles/PMC521080/
10. Marquez, A. B., Vicente, J., Castro, E., Vota, D., Rodríguez-Varela, M. S., Lanza Castronuovo, P. A., Fuentes, G. M., Parise, A. R., Romorini, L., Alvarez, D. E., Bueno, C. A., Ramirez, C. L., Alaimo, A., & García, C. C. (2024). Broad-spectrum antiviral effect of cannabidiol against enveloped and nonenveloped viruses. Cannabis and Cannabinoid Research, 9(3), 751–765.doi.org/10.1089/can.2023.0103
11. Sharma, R. P., & Reddy, P. M. (2023). Cannabinoids in immune modulation: Antiviral activities. Journal of Antiviral Research.pmc.ncbi.nlm.nih.gov/articles/PMC10133872/
12. Ninfali, P., Antonelli, A., Magnani, M., & Scarpa, E. S. (2020). Antiviral Properties of Flavonoids and Delivery Strategies. Nutrients, 12(9), 2534. doi.org/10.3390/nu12092534
13. Volker, M. (2020). Neuroinflammation and cannabinoids. ScienceDirect.www.sciencedirect.com/science/article/abs/pii/S0171298509001880
14. Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel), 9(1), 21.doi.org/10.3390/antiox9010021
15. Astani, A., & Schnitzler, P. (2014). Antiviral activity of monoterpenes beta-pinene and limonene against herpes simplex virus in vitro. Iranian Journal of Microbiology, 6(3), 149–155. doi.org/PMCID: PMC4393490  
16. Nagoor Meeran, M. F., Seenipandi, A., Javed, H., Sharma, C., Hashiesh, H. M., Goyal, S. N., Jha, N. K., & Ojha, S. (2021). Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19? Heliyon, 7(1), e05703.doi.org/10.1016/j.heliyon.2020.e05703
17. Sea, Y. L., Gee, Y. J., Lal, S. K., & Choo, W. S. (2023). Cannabis as antivirals. Journal of Applied Microbiology, 134(1), lxac036.doi.org/10.1093/jambio/lxac036
18. Ninfali, P., Antonelli, A., Magnani, M., & Scarpa, E. S. (2020). Antiviral Properties of Flavonoids and Delivery Strategies. Nutrients, 12(9), 2534. doi.org/10.3390/nu12092534
19. Fitzpatrick, J.-M. K., O’Riordan, D., & Downer, E. J. (2024). Cannflavin A inhibits TLR4-induced chemokine and cytokine expression in human macrophages. Natural Product Research.doi.org/10.1080/14786419.2024.2358382
20. Mahmud, M. S., Hossain, M. S., Ahmed, A. T. M. F., Islam, M. Z., Sarker, M. E., & Islam, M. R. (2021). Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and Cannabis sativa: A Comprehensive Review. Molecules, 26(23), 7216. doi.org/10.3390/molecules26237216
21. BioSource Botanicals (2024). The power of activated cannabis extracts. biosourcebotanicals.com/the-power-of-activated-full-spectrum-cannabis-extracts-why-preserving-natures-balance-protects-the-therapeutic-potential-of-the-entire-plant